The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy

Abstract

[...]they have become a promising approach to treat graft-versus-host disease (GVHD) and autoimmune disease because of their immunomodulatory properties and low immunogenicity [7-9]. [...]some systemic diseases, such as diabetes [12], rheumatoid arthritis [13], and systemic lupus erythematosus (SLE) [14], alter the intrinsic properties of MSCs, thus impairing their protective function. [...]MSCs inhibit the activity of various immune cells, including T cells, B cells, natural killer cells, and dendritic cells via cell-cell contacts and soluble factors [16, 17].